Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment
- 8 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (11) , 5436-5446
Abstract
In 2016 specific heterozygous gain-of-function mutations in the Mediterranean fever gene MEFV were reported as causal for a distinct autoinflammatory disease coined pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). We sought to provide an extended report on clinical manifestations in PAAND patients to date and evaluate the efficacy and safety of treatment with the IL-1-blocking agent anakinra. We undertook an open-label pilot study with anakinra. Three patients were recruited in a preliminary phase of the study with the intention to expand the treatment cohort in case of a favourable response. Acute-phase reactants and plasma cytokine levels were monitored throughout. Skin biopsies at baseline and at week 12 were stained for relevant cytokines. Available clinical data on treatment responses were retrospectively collected on additional patients. The three patients from the preliminary phase of the study [patients 1–3 (P1–P3)] demonstrated one failed and two partial treatment responses, where one patient opted to continue treatment with anakinra and the other favoured adalimumab. While a partial systemic response was observed, there was no appreciable effect of anakinra on the prominent cutaneous manifestations, reflected in residual local inflammatory cytokine expression in lesional skin. These observations did not warrant further expansion of the treatment cohort. Clinical data was retrospectively collected on an additional eight patients (P4–P11), highlighting both dominant and recessive inheritance with variable penetrance in PAAND and common gastrointestinal involvement that was not previously appreciated. In our experience, while anakinra appears safe, it was not superior to biologicals targeting TNF-α in PAAND despite evidence directly implicating dysregulated IL-1β signalling.Keywords
Funding Information
- European Union’s Horizon 2020 (779295)
- KU Leuven
- Biotechnology and Biological Sciences Research Council
- Institute Strategic Program Grant (BBS/E/B/000C0427, BBS/E/B/000C0428)
- Research Foundation Flanders (1S22716N)
This publication has 13 references indexed in Scilit:
- Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)British Journal of Dermatology, 2017
- Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acneInternational Journal of Dermatology, 2017
- PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and TreatmentAmerican Journal of Clinical Dermatology, 2017
- Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammationBritish Journal of Dermatology, 2016
- Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activationProceedings of the National Academy of Sciences, 2016
- Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activationScience Translational Medicine, 2016
- Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasomeNature, 2014
- High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connectionArthritis Research & Therapy, 2013
- Injection-site reactions upon Kineret (anakinra) administration: experiences and explanationsRheumatology International, 2011
- Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory SyndromesCell, 1999